Lavie Bio announces appointment of Amit Noam as its incoming Chief Executive Officer

Lavie Bio Ltd. ("Lavie Bio"), a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), and a leading ag-biologicals company focusing on improving food quality, sustainability, and agriculture productivity through the introduction of microbiome-based products, announced the appointment of Mr. Amit Noam as Chief Executive Officer ("CEO") of Lavie Bio, effective as of April 16, 2023.

Mr. Noam has extensive experience as a senior executive, particularly in the agriculture and healthcare sectors, leading teams in the development and execution of commercialization strategies, driving long-term growth and value-creation for businesses. Since 2018, Mr. Noam served as Chief Operating Officer of AgriTask, an ag-tech company, leading the company's commercial and operational strategies, as well as successfully supporting multiple fund-raising rounds. He also has previous experience with leading pharma company, Teva Pharmaceuticals, as well as Shaldor, an Israeli consulting firm, and Themis UAV, providing robotics solutions.

Mr. Noam holds an MBA from Tel Aviv University and a BSc in Industrial and Management Engineering from Ben-Gurion University in Beer Sheva, Israel.

Amit Noam, incoming CEO of Lavie Bio, stated, "I have a passion for technological innovation that positively impacts society. I strongly believe in Lavie Bio's vision of improving food quality, agricultural sustainability, and productivity through ag-biological products, built using Evogene's strong underlying AI tech-engines. Furthermore, Lavie Bio has a string of impressive achievements, as well as world leading partners and investors supporting it, namely Corteva and ICL Group. I am honored to have been given this opportunity to assume the CEO position of Lavie Bio, and I am excited to be joining the company at this key juncture in its development."

Ofer Haviv, Lavie Bio Chairperson & Evogene's President and CEO, added, "We are delighted to welcome Amit to the Evogene Group, to assume the leadership of Lavie Bio. Amit has a strong track record in leading early-stage companies through their commercial development stages, and I believe he is the right candidate to lead Lavie Bio. I believe he will prove instrumental in advancing the goals of the company, especially as we scale up manufacturing and increase sales for our bio-stimulant, Thrivus™, advance our pipeline including LAV311 (Lavie Bio's novel bio-fungicide targeted for a commercial launch in 2024), and extend the scope of our collaborations with our leading global partners".